source
- FDA questions efficacy of Capricor's Duchenne muscular dystrophy cell therapy ahead of advisory committeeFDA reviewers have raised concerns about the efficacy of Capricor's cell therapy for Duchenne muscular dystrophy as the agency prepares for an advisory committee meeting. The agency said it could n…
- MapLight shares plunge 66% after mid-stage schizophrenia trial shows modest benefit but raises competitive concernsMapLight Therapeutics announced results from its mid‑stage trial of an experimental schizophrenia drug. The study enrolled adults experiencing an acute exacerbation of psychotic symptoms. The twic…